British Columbia says it will save more than $96 million in its prescription drug program by expanding the use of so-called biosimilar drugs to treat diabetes, arthritis and Crohn's disease.
With the cost of insulin on the rise in the U.S., more Americans are crossing the border to buy the drug in Canada, where is it one-tenth of the price for patients.
